Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
| Autor: | Taehee Kim, Min Kyong Moon, Tae Jung Oh, Hyun Jung Kim, Dong Won Lee, Seung Hyun Ko, Ju Young Moon, Kyu Yeon Hur |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Nephrology
lcsh:Internal medicine medicine.medical_specialty Consensus lcsh:Specialties of internal medicine Diabetic ketoacidosis Endocrinology Diabetes and Metabolism 030232 urology & nephrology Renal function 030209 endocrinology & metabolism Review Disease 030204 cardiovascular system & hematology lcsh:Diseases of the endocrine glands. Clinical endocrinology Special Article 03 medical and health sciences Diabetes mellitus 0302 clinical medicine lcsh:RC581-951 Internal medicine Republic of Korea medicine sodium-glucose transporter 2 inhibitors Humans Hypoglycemic Agents Guideline/Fact Sheet Sodium-glucose transporter-2 inhibitors lcsh:RC31-1245 Adverse effect glomerular filtration rate lcsh:RC648-665 business.industry Sodium Type 2 Diabetes Mellitus General Medicine medicine.disease Clinical trial Glucose Pharmaceutical Preparations type 2 diabetes mellitus type 2 SGLT2 Inhibitor business |
| Zdroj: | Diabetes & Metabolism Journal, Vol 44, Iss 4, Pp 489-497 (2020) Kidney Research and Clinical Practice Kidney Research and Clinical Practice, Vol 39, Iss 3, Pp 269-283 (2020) Diabetes & Metabolism Journal |
| ISSN: | 2233-6087 2233-6079 |
| Popis: | Diabetes is a leading cause of end-stage renal disease. Therefore, prevention of renal dysfunction is an important treatment goal in the management of diabetes. The data of landmark cardiovascular outcome trials of sodium-glucose cotransporter-2 (SGLT2) inhibitors showed profound reno-protective effects. The Korean Diabetes Association and the Korean Society of Nephrology reviewed clinical trials and performed a meta-analysis to assess the effects of SGLT2 inhibitors on the preservation of estimated glomerular filtration rate (eGFR). We limited the data of SGLT2 inhibitors which can be prescribed in Korea. Both eGFR value and its change from the baseline were significantly more preserved in the SGLT2-inhibitor treatment group compared to the control group after 156 weeks. However, some known adverse events were increased in SGLT2 inhibitor treatment, such as genital infection, diabetic ketoacidosis, and volume depletion. We recommend long-term use of SGLT2 inhibitors in patients with type 2 diabetes mellitus (T2DM) for attenuation of renal function decline. However, we cannot generalize our recommendations due to the lack of long-term clinical trials testing the reno-protective effects of every SGLT2 inhibitor in a broad range of patients with T2DM. This recommendation can be revised and updated after the publication of several large-scale renal outcome trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|